NORDIC BIOSCIENCE A/S

Their core work

Nordic Bioscience is a Danish biotech SME specializing in biomarker discovery and development for chronic diseases, particularly liver and musculoskeletal conditions. They develop blood-based diagnostic tools and validated biomarkers that can detect disease progression earlier than conventional methods. Their core competence lies in translating biological markers from research into clinically useful diagnostics, contributing biomarker expertise to large European research consortia studying liver fibrosis, steatohepatitis, Alzheimer's disease, and bone pain.

What they specialise in

How they've shifted over time

In their early H2020 period (2015-2017), Nordic Bioscience spread across diverse disease areas — bone pain, fatty liver pathways, and Alzheimer's diagnostics — essentially offering their biomarker platform wherever it could be applied. From 2019 onward, their focus sharpened significantly toward liver disease, with LITMUS becoming their largest project and DECISION pushing into advanced cirrhosis and systems-level omics analysis. This trajectory suggests a strategic narrowing from generalist biomarker company to liver disease diagnostics specialist.

Nordic Bioscience is consolidating around liver disease biomarkers and increasingly integrating omics and systems biology, positioning them as a go-to partner for non-invasive liver diagnostics in future consortia.

How they like to work

Nordic Bioscience operates exclusively as a consortium participant, never as coordinator — typical for a specialized SME that contributes deep technical expertise rather than project management capacity. With 115 unique partners across 20 countries in just 7 projects, they consistently join large, multi-partner consortia (averaging 16+ partners per project). This pattern indicates they are well-connected and trusted within the European biomarker and clinical research community, but rely on academic or institutional partners to lead projects.

Extensive network of 115 unique partners across 20 countries, built through large clinical research consortia. Their connections span major European university hospitals, pharma companies, and research institutes involved in liver and musculoskeletal research.

What sets them apart

Nordic Bioscience occupies a distinctive niche as a private biomarker company that bridges the gap between academic discovery and clinical diagnostics. Unlike university labs that publish biomarker papers, they focus on translating and validating biomarkers into commercially viable diagnostic products. For consortium builders, they bring proprietary biomarker assay platforms and extensive clinical sample analysis capabilities that academic partners typically cannot match.

Highlights from their portfolio

• LITMUS
  Their largest project (EUR 1.4M) and a flagship European effort to validate biomarkers for non-alcoholic fatty liver disease — one of the most commercially relevant liver diagnostics challenges.
• DECISION
  Their most recent project, marking a strategic shift toward systems biology and combinatorial therapy approaches for advanced cirrhosis, running until 2026.
• BBDiag
  Demonstrates their biomarker platform's versatility beyond liver disease, applying blood-based diagnostics to early Alzheimer's detection — a massive unmet clinical need.